Last €12.50 EUR
Change Today -0.087 / -0.69%
Volume 0.0
HALOZ On Other Exchanges
Symbol
Exchange
Frankfurt
As of 4:06 AM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALOZ) Snapshot

Open
€12.64
Previous Close
€12.59
Day High
€12.72
Day Low
€12.50
52 Week High
01/20/15 - €13.08
52 Week Low
05/7/14 - €4.99
Market Cap
1.6B
Average Volume 10 Days
1.3K
EPS TTM
--
Shares Outstanding
125.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HALOZYME THERAPEUTICS INC (HALOZ)

halozyme therapeutics inc (HALOZ) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALOZ) Details

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of pancreatic cancer; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; and Baxter Healthcare Corporation. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

170 Employees
Last Reported Date: 02/28/14
Founded in 1998

halozyme therapeutics inc (HALOZ) Top Compensated Officers

Chief Financial Officer and Vice President
Total Annual Compensation: $314.9K
Chief Scientific Officer and Vice President
Total Annual Compensation: $321.4K
Consultant
Total Annual Compensation: $366.7K
Compensation as of Fiscal Year 2013.

halozyme therapeutics inc (HALOZ) Key Developments

Halozyme Therapeutics, Inc. Appoints Jean-Pierre Bizzari, M.D. to its Board of Directors

Halozyme Therapeutics, Inc. announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari was Group Head, Clinical Oncology Development at Celgene Corporation, a role he held since 2008. In addition, he was Chairman of Celgene's hematology oncology development committee and a member of the company's management committee. Dr. Bizzari is a member of the Scientific Advisory Board of France'sNational Cancer Institute and is a board member of Transgene.

Halozyme Therapeutics, Inc. Plans to Initiate Trial to Evaluate PEGPH20; Provides Financial Guidance for the Year 2015

Halozyme Therapeutics, Inc. anticipate expanding and accelerating the company's PEGPH20 clinical development efforts. In pancreatic cancer, the company's goal is to complete Study 202 enrollment and gain feedback from regulatory authorities on plans to initiate a registration trial for PEGPH20 in pancreatic cancer patients whose tumors accumulate high levels of hyaluronan (HA). In NSCLC, in addition to completing enrollment in the Phase 1b portion of the PRIMAL trial and initiating Phase 2, the company plan to initiate a trial to evaluate PEGPH20 in combination with a PD-1 inhibitor. Present Phase 1b (Study 201) results at ASCO-GI (poster scheduled for January 16, 2015). Complete patient enrollment in the on-going Phase 2 multi-center, randomized clinical trial (Study 202) evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer, in the second half of 2015. During the first half of 2015, the company plans to meet with the regulatory authorities to discuss the current benefit:risk of PEGPH20 and plans to initiate a registration study for PEGPH20 in metastatic pancreatic cancer. Initiate patient enrollment and dosing for a registration trial in the fourth quarter of 2015 or the first quarter of 2016, pending regulatory feedback. PEGPH20 in Combination with docetaxel (NSCLC Program). Complete patient enrollment in the on-going global Phase 1b multi-center, randomized clinical trial (PRIMAL) evaluating PEGPH20 as a second-line therapy for patients with locally advanced or metastatic NSCLC in the third quarter of 2015, pending the number of dose escalation cohorts of PEGPH20. The Phase 1b study will include both a dose escalation and dose expansion phase evaluating two different schedules. Initiate patient enrollment and dosing for the Phase 2 randomized portion of the clinical trial following the evaluation of the Phase 1b data. PEGPH20 in Combination with a PD-1 Inhibitor. Initiate a Phase 1b open label multicenter, randomized clinical trial evaluating PEGPH20 as a second-line therapy for patients with locally advanced or metastatic NSCLC whose tumors accumulate high levels of HA, in the second half of 2015. Collaboration Products: ENHANZE is Halozyme's proprietary drug delivery platform based on the Company's patented recombinant human hyaluronidase enzyme (rHuPH20). Throughout 2015, Halozyme intends to provide support for ongoing launch activities for Herceptin SC, MabThera SC and HYQVIA, as well as support the efforts of the company's collaborative partners to develop and apply ENHANZE technology to their respective targets. The company provided financial guidance for the year 2015. The company ended 2014 with approximately $135 million in cash, cash equivalents and marketable securities (these results are unaudited) and does not anticipate the need for dilutive financing to fund operations. For the full year 2015, the company expects: Net revenues to be in the range of $85 million to $95 million. Operating expenses to be in the range of $145 million to $155 million. Net cash burn to be between $35 million and $45 million.

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2015

Halozyme Therapeutics, Inc. provided earnings guidance for the full year 2015. For the full year 2015, the company expects net revenues to be in the range of $85 million to $95 million. Net cash burn to be between $35 million and $45 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALOZ:GR €12.50 EUR -0.087

HALOZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $12.24 USD +0.47
View Industry Companies
 

Industry Analysis

HALOZ

Industry Average

Valuation HALOZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.9x
Price/Book 43.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit www.halozyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.